Celularity Stock Performance
| CELU Stock | USD 4.20 0.09 2.19% |
Celularity holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 4.97, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Celularity will likely underperform. Use Celularity downside variance, and the relationship between the sortino ratio and accumulation distribution , to analyze future returns on Celularity.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Celularity are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak essential indicators, Celularity unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.19 | Five Day Return (14.11) | Year To Date Return 50 | Ten Year Return (95.71) | All Time Return (95.71) |
Last Split Factor 1:10 | Last Split Date 2024-02-29 |
1 | Celularitys Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem ... | 02/14/2024 |
2 | Disposition of 571 shares by Fletcher Kyle of Celularity at 0.434 subject to Rule 16b-3 | 02/16/2024 |
3 | Acquisition by Hariri Robert J of 2937788 shares of Celularity subject to Rule 16b-3 | 02/21/2024 |
4 | Stocks to Watch Intuitive Machines, Celularity | 02/23/2024 |
5 | Acquisition by Lim Kok Thay of 300000 shares of Celularity at 5.895 subject to Rule 16b-3 | 03/13/2024 |
6 | Celularity CEO to Present on Cell Therapys Potential to Improve Longevity at 2024 ABUNDANCE Summit | 03/14/2024 |
7 | Disposition of 617 shares by Fletcher Kyle of Celularity at 5.68 subject to Rule 16b-3 | 03/15/2024 |
8 | Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy | 03/20/2024 |
9 | Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare Medicaid Services for Biovance 3L | 03/26/2024 |
10 | Celularity, Inc. Is a Trending Stock Facts to Know Before Betting on It - Yahoo Movies UK | 04/02/2024 |
11 | Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024 Implements Planned 2024 SGA Reductions and Manufacturing Ramp for Advanced ... | 04/15/2024 |
| Begin Period Cash Flow | 57.5 M |
Celularity |
Celularity Relative Risk vs. Return Landscape
If you would invest 188.00 in Celularity on January 17, 2024 and sell it today you would earn a total of 232.00 from holding Celularity or generate 123.4% return on investment over 90 days. Celularity is currently generating 1.8099% in daily expected returns and assumes 10.8377% risk (volatility on return distribution) over the 90 days horizon. In different words, 95% of stocks are less volatile than Celularity, and 65% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Celularity Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Celularity's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Celularity, and traders can use it to determine the average amount a Celularity's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.167
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CELU | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.84 actual daily | 95 95% of assets are less volatile |
Expected Return
| 1.81 actual daily | 35 65% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Celularity is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Celularity by adding it to a well-diversified portfolio.
Celularity Fundamentals Growth
Celularity Stock prices reflect investors' perceptions of the future prospects and financial health of Celularity, and Celularity fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Celularity Stock performance.
| Return On Equity | -1.87 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (4.31) % | ||||
| Current Valuation | 142.19 M | ||||
| Shares Outstanding | 21.78 M | ||||
| Price To Earning | 3.08 X | ||||
| Price To Book | 2.95 X | ||||
| Price To Sales | 6.05 X | ||||
| Revenue | 14.79 M | ||||
| Gross Profit | (1.69 M) | ||||
| EBITDA | (87.91 M) | ||||
| Net Income | (181.41 M) | ||||
| Cash And Equivalents | 42.65 M | ||||
| Cash Per Share | 0.29 X | ||||
| Total Debt | 65.59 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 0.91 X | ||||
| Book Value Per Share | 1.56 X | ||||
| Cash Flow From Operations | (63.93 M) | ||||
| Earnings Per Share | (10.30) X | ||||
| Market Capitalization | 91.49 M | ||||
| Total Asset | 401.07 M | ||||
| Retained Earnings | (645.5 M) | ||||
| Working Capital | (28.59 M) | ||||
About Celularity Performance
To evaluate Celularity Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Celularity generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Celularity Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Celularity market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Celularity's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 113.30 | 107.63 | |
| Return On Tangible Assets | 0.08 | 0.08 | |
| Return On Capital Employed | (0.09) | (0.09) | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.08 | 0.09 |
Things to note about Celularity performance evaluation
Checking the ongoing alerts about Celularity for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Celularity help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Celularity is way too risky over 90 days horizon | |
| Celularity appears to be risky and price may revert if volatility continues | |
| Celularity has high likelihood to experience some financial distress in the next 2 years | |
| The company currently holds 65.59 M in liabilities with Debt to Equity (D/E) ratio of 0.41, which is about average as compared to similar companies. Celularity has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Celularity until it has trouble settling it off, either with new capital or with free cash flow. So, Celularity's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Celularity sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Celularity to invest in growth at high rates of return. When we think about Celularity's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 14.79 M. Net Loss for the year was (181.41 M) with loss before overhead, payroll, taxes, and interest of (1.69 M). | |
| Celularity currently holds about 42.65 M in cash with (63.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29. | |
| Roughly 51.0% of Celularity shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024 Implements Planned 2024 SGA Reductions and Manufacturing Ramp for Advanced Biomaterial Products |
- Analyzing Celularity's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Celularity's stock is overvalued or undervalued compared to its peers.
- Examining Celularity's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Celularity's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Celularity's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Celularity's stock. These opinions can provide insight into Celularity's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celularity. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Celularity Stock please use our How to Invest in Celularity guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Celularity Stock analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Celularity's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celularity. If investors know Celularity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celularity listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share (10.30) | Revenue Per Share 0.887 | Quarterly Revenue Growth (0.08) | Return On Assets (0.20) |
The market value of Celularity is measured differently than its book value, which is the value of Celularity that is recorded on the company's balance sheet. Investors also form their own opinion of Celularity's value that differs from its market value or its book value, called intrinsic value, which is Celularity's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celularity's market value can be influenced by many factors that don't directly affect Celularity's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Celularity's value and its price as these two are different measures arrived at by different means. Investors typically determine if Celularity is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celularity's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.